These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 23712796)

  • 1. Evidence for the benefits of nonantipsychotic pharmacological augmentation in the treatment of depression.
    Chang CM; Sato S; Han C
    CNS Drugs; 2013 May; 27 Suppl 1():S21-7. PubMed ID: 23712796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies.
    Connolly KR; Thase ME
    Drugs; 2011 Jan; 71(1):43-64. PubMed ID: 21175239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What are the comparative benefits and harms of augmentation treatments in major depression?
    Shelton RC
    J Clin Psychiatry; 2015 Apr; 76(4):e531-3. PubMed ID: 25919851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis.
    Zhou X; Ravindran AV; Qin B; Del Giovane C; Li Q; Bauer M; Liu Y; Fang Y; da Silva T; Zhang Y; Fang L; Wang X; Xie P
    J Clin Psychiatry; 2015 Apr; 76(4):e487-98. PubMed ID: 25919841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of augmentation strategies for patients with major depressive disorder.
    Fleurence R; Williamson R; Jing Y; Kim E; Tran QV; Pikalov AS; Thase ME
    Psychopharmacol Bull; 2009; 42(3):57-90. PubMed ID: 19752841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can Atypical Antipsychotic Augmentation Reduce Subsequent Treatment Failure More Effectively Among Depressed Patients with a Higher Degree of Treatment Resistance? A Meta-Analysis of Randomized Controlled Trials.
    Wang HR; Woo YS; Ahn HS; Ahn IM; Kim HJ; Bahk WM
    Int J Neuropsychopharmacol; 2015 Mar; 18(8):. PubMed ID: 25770098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic approaches to treatment resistant depression: Evidences and personal experience.
    Tundo A; de Filippis R; Proietti L
    World J Psychiatry; 2015 Sep; 5(3):330-41. PubMed ID: 26425446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmentation strategies for treatment-resistant depression.
    Carvalho AF; Machado JR; Cavalcante JL
    Curr Opin Psychiatry; 2009 Jan; 22(1):7-12. PubMed ID: 19122528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Augmentation of antidepressants with atypical antipsychotics in non-delusional unipolar depressed patients with non-response to antidepressant-monotherapy].
    Erbe S; Gutwinski S; Bschor T
    Psychiatr Prax; 2012 Mar; 39(2):57-63. PubMed ID: 22189902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The integrative management of treatment-resistant depression: a comprehensive review and perspectives.
    Carvalho AF; Berk M; Hyphantis TN; McIntyre RS
    Psychother Psychosom; 2014; 83(2):70-88. PubMed ID: 24458008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium.
    Vázquez GH; Bahji A; Undurraga J; Tondo L; Baldessarini RJ
    J Psychopharmacol; 2021 Aug; 35(8):890-900. PubMed ID: 34238049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis.
    Nuñez NA; Joseph B; Pahwa M; Kumar R; Resendez MG; Prokop LJ; Veldic M; Seshadri A; Biernacka JM; Frye MA; Wang Z; Singh B
    J Affect Disord; 2022 Apr; 302():385-400. PubMed ID: 34986373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic options for treatment-resistant depression.
    Shelton RC; Osuntokun O; Heinloth AN; Corya SA
    CNS Drugs; 2010 Feb; 24(2):131-61. PubMed ID: 20088620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmentation treatments with second-generation antipsychotics to antidepressants in treatment-resistant depression.
    Kato M; Chang CM
    CNS Drugs; 2013 May; 27 Suppl 1():S11-9. PubMed ID: 23709358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of lithium augmentation in the management of major depressive disorder.
    Bauer M; Adli M; Ricken R; Severus E; Pilhatsch M
    CNS Drugs; 2014 Apr; 28(4):331-42. PubMed ID: 24590663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study protocol for the randomised controlled trial: antiglucocorticoid augmentation of anti-Depressants in Depression (The ADD Study).
    McAllister-Williams RH; Smith E; Anderson IM; Barnes J; Gallagher P; Grunze HC; Haddad PM; House AO; Hughes T; Lloyd AJ; McColl EM; Pearce SH; Siddiqi N; Sinha B; Speed C; Steen IN; Wainright J; Watson S; Winter FH; Ferrier IN
    BMC Psychiatry; 2013 Aug; 13():205. PubMed ID: 23914988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression.
    Nelson JC; Baumann P; Delucchi K; Joffe R; Katona C
    J Affect Disord; 2014 Oct; 168():269-75. PubMed ID: 25069082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment.
    Dold M; Bartova L; Kasper S
    Int J Neuropsychopharmacol; 2020 Jul; 23(7):440-445. PubMed ID: 32570275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Augmentation of standard depression therapy.
    Marangell LB
    Clin Ther; 2000; 22 Suppl A():A25-38; discussion A39-41. PubMed ID: 10815648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using adjunctive treatments when first-line antidepressants fail.
    Thase ME
    J Clin Psychiatry; 2012 Jan; 73(1):e01. PubMed ID: 22316580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.